ClinicalTrials.gg
Not yet recruitingNCT06775236Updated Mar 19, 2025

Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors

A Phase 1/2 interventional study of SYS6010 jnjection and monotherapy chemotherapy in Advanced Solid Tumors and Breast Cancer, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Breast Neoplasms by CSPC Pharmaceutical Group Limited — 16 open to participants now, 18 under way, 10 of them phase 3. Breast Neoplasms · CSPC Pharmaceutical Group Limited.

Planned enrollment
10th of 26
410 · median 270
Started
2025
with 5 others
Phase 1/2
Only one
of the 26
Primary completion
2027-06
later than 12 of 17 live
Registered
15th of 26
by date

Among the 26 studies in Breast Neoplasms by CSPC Pharmaceutical Group Limited, this one is the 10th largest by planned enrollment, is one of 6 that started in 2025, is the only one in phase 1/2, reaches primary completion later than 12 of the 17 other live ones, and was the 15th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 26 studies in Breast Neoplasms by CSPC Pharmaceutical Group Limited are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Breast Neoplasms by CSPC Pharmaceutical Group Limited, or all of them as a file.
02

Study summary

The study consists of two phases. Phase 1b and Phase 2. Phase 1b aims to evaluate the safety, tolerability, and preliminary efficacy of SYS6010 as a monotherapy and in combination with SYH2051, and to determine the recommended Phase 2 dose (RP2D) for subsequent Phase 2 studies. Phase 2 aims to assess the efficacy and safety of SYS6010 monotherapy or in combination with SYH2051 compared to investigator-selected chemotherapy in patients with EGFR-expressing, unresectable locally advanced or metastatic advanced breast cancer.

Read the detailed description

Phase Ⅰb Design:

Group A (SYS6010 3.2 mg/kg, Q2W):

Monotherapy Cohort: Planned enrollment of 8-12 breast cancer patients to evaluate the safety and preliminary efficacy of SYS6010 monotherapy.

Combination Cohort: Includes dose-escalation and expansion phases. Dose-escalation phase: A "3+3" design will be used to explore the safety of SYS6010 combined with SYH2051, with SYH2051 doses ranging from 60-80 mg.

Expansion phase: Upon completion of dose-escalation and confirmation of safety, breast cancer patients may be enrolled in the expansion phase.

Group B (SYS6010 3.6 mg/kg, Q2W):

Monotherapy Cohort: Planned enrollment of 8-12 breast cancer patients. Combination Cohort: Similar to Group A, with SYH2051 doses ranging from 40-60 mg.

Group C (SYS6010 3.6 mg/kg, Q2W): Enroll 40 EGFR-expressing HR+/HER2- breast cancer patients to further evaluate the safety and efficacy in this specific population.

Phase Ⅱ Design:

Based on molecular subtypes of breast cancer, cohort studies will be conducted.

Each cohort will enroll 125 patients, randomized in a 2:2:1 ratio into three groups:

SYS6010 + SYH2051 SYS6010 monotherapy Chemotherapy control.

03

Conditions studied

  • Advanced Solid Tumors
  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Age ≥ 18 years. 2. Phase 1b/Phase 2: Breast cancer (no tumor type restriction during the combination dose escalation phase).

      1. Provide tumor tissue samples for immunohistochemical EGFR expression testing, with EGFR expression positive as confirmed by the central laboratory.
      1. At least one measurable extracranial lesion according to v1.1 criteria (no requirement during the combination dose escalation phase of Phase 1b).
      1. performance status score of 0-1. 6. Expected survival ≥ 3 months. 7. Major organ function meets the relevant laboratory test standards for hematology, renal function, liver function, and coagulation within 7 days prior to treatment.
      1. Subject agrees to use effective from the time of signing the form until 6 months after the last dose.
      1. Willing to participate in the study, understand the study procedures, and sign a written informed consent form.

Exclusion criteria

Exclusion Criteria:

    1. Active central nervous system (CNS) or carcinomatous meningitis. Patients with treated and stable are eligible for inclusion.

      1. Previously diagnosed -positive breast cancer (IHC 3+ or ISH positive) (Applicable to Phase 1b Group C and Phase 2).
      1. Previously treated with antibody-drug conjugates (ADC) containing topoisomerase I inhibitors (Applicable to Phase 1b Group C and Phase 2).
      1. Allergy to any component of SYS6010 or SYH2051, or to humanized monoclonal antibodies.
      1. Allergy to any component of SYS6010 or SYH2051, or to humanized monoclonal antibodies (This is a repeat of criteria #4).
      1. Adverse events from prior antitumor therapy not recovered to ≤ Grade 1 (unless the investigator deems there is no safety risk).
      1. Failure to meet the required for prior medications or treatments as specified in the protocol.
      1. History of severe cardiovascular or cerebrovascular diseases. 9. History of interstitial lung disease (ILD) / non-infectious pneumonia, or current ILD/non-infectious pneumonia, or imaging findings at screening that cannot rule out these conditions.
      1. Thyroid dysfunction requiring medication, unless the condition is controlled by medication and no dose adjustments are needed.
      1. Severe infection within 4 weeks prior to the first use of the drug.
      1. History of discontinuing EGFR-targeted therapy for ≥ 1 month due to skin toxicity, or current skin conditions requiring medication.
      1. Gastrointestinal diseases or functional impairments that may significantly affect the absorption of the investigational drug (e.g., ulcerative disease, severe nausea/vomiting, diarrhea, malabsorption, etc.).
      1. Uncontrolled pleural or peritoneal effusion. 15. Active or infection, syphilis, infection, or AIDS. 16. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
410 participants (estimated)

Study arms

  • Experimental
    SYS6010 injection

    SYS6010 injection 3.2 mg/kg or 3.6 mg/kg, intravenous drip, Q2W

    Drug: SYS6010 jnjection

  • Experimental
    SYS6010 injection + SYH2051 tablets

    SYS6010 injection 3.2 mg/kg intravenous drip + SYH2051 60 or 80 mg, oral, Q2W Or SYS6010 injection 3.6 mg/kg intravenous drip + SYH2051 40 or 60 mg, oral, Q2W

    Drug: SYS6010 jnjection · Drug: SYH2051 tablets

  • Active comparator
    Monotherapy Chemotherapy Group

    Investigator's choice of monotherapy chemotherapy (Eribulin, Capecitabine, Gemcitabine, Vinorelbine, or Taxanes. )

    Drug: monotherapy chemotherapy

Interventions

  • SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker

  • Drugmonotherapy chemotherapy

    Investigator's choice of monotherapy chemotherapy (Eribulin, Capecitabine, Gemcitabine, Vinorelbine, or Taxanes.)

  • SYH2051 is a Selective ATM protein kinase inhibitor

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity(DLT) occurrence and incidence

    The occurrence and incidence of dose-limiting toxicities (DLTs) will be assessed based on predefined criteria during the first 28 days after the initial dose. DLTs are defined as adverse events related to the study drug that meet the protocol-specified criteria for dose limitation.

    Time frame: Up to approximately 3 months after the first participant is enrolled

  2. Adverse events (AE) occurrence and incidence

    The occurrence and incidence of adverse events (AEs) will be evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. AEs will be monitored from the first dose until the safety follow-up period.

    Time frame: Up to approximately 36 months after the first participant is enrolled

  3. Objective response rate (ORR) per RECIST v1.1

    The objective response rate (ORR) will be assessed based on RECIST v1.1 criteria. ORR is defined as the proportion of patients achieving a complete response (CR) or partial response (PR) as the best overall response.

    Time frame: Up to approximately 36 months after the first participant is enrolled

Secondary outcomes

  1. Disease control rate (DCR) per RECIST 1.1

    Time frame: Up to approximately 36 months after the first participant is enrolled

  2. Duration of response (DoR) per RECIST 1.1

    Time frame: Up to approximately 36 months after the first participant is enrolled

  3. Progression free survival (PFS) per RECIST 1.1

    Time frame: Up to approximately 36 months after the first participant is enrolled

  4. Overall survival(OS)

    Time frame: Up to approximately 36 months after the first participant is enrolled

  5. PK parameters of toxin-bound antibody

    Time frame: Up to approximately 36 months after the first participant is enrolled

  6. Description :total antibody and free toxin (JS-1) after single and continuous administration of SYS6010

    Time frame: Up to approximately 36 months after the first participant is enrolled

  7. PK parameters after single and multiple administrations of SYH2051

    Time frame: Up to approximately 36 months after the first participant is enrolled

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Jun 2027, 26 months later.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 26 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2025
First posted
Jan 15, 2025
StartEst.
Mar 20, 2025
Primary completionEst.
Jun 15, 2027
CompletionEst.
Jan 15, 2028
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06775236
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Mar 20, 2025 (estimated)
Primary completion
Jun 15, 2027 (estimated)
Completion
Jan 15, 2028 (estimated)
Last update
Mar 19, 2025

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-EGFR Antibody-drug Conjugate CPO301 · ATM Inhibitor SYH2051

Start the discussion